China SXT Pharmaceuticals vs XTL Biopharmaceuticals
SXTC and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SXTC and XTLB compare
China SXT Pharmaceuticals scores higher on the StockData Score (4 against 0 for XTL Biopharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SXTC | XTLB |
|---|---|---|
| Size and price | ||
| Share price | $2.73 | $1.64 |
| Change, 1 year | −100.0% | −58.6% |
| Change, 5 years | −100% | −87.6% |
| Beta (5Y) | – | 0.99 |
| Employees | 56 | 3 |
| StockData Score | ||
| Total score | 4 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −34.6% | – |
| Revenue growth, 5Y average | −24.9% | – |
| Profitability | ||
| Gross margin | 21.9% | – |
| Operating margin | −626% | – |
| Net margin | −545% | – |
| Return on equity | −27.5% | – |
| Return on invested capital | −1657% | – |
| Financial health | ||
| Debt / equity | 0.03 | – |
| Interest coverage | −113.1× | −6.3× (better) |
| Current ratio | 7.93 | – |
| Piotroski F-score | 3 | – |
| Ownership | ||
| Held by institutions | – | 0.00% |
| Held by insiders | 0.00% | 0.00% |
| Short interest, % of float | 2.9% | – |
Go deeper
- SXTC stock overview
- SXTC income statement
- SXTC valuation and score
- XTLB stock overview
- XTLB income statement
- XTLB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.